Yusheng Liao

发表

Discovery of Highly Isoform Selective Thiazolopiperidine Inhibitors of Phosphoinositide 3-Kinase γ.

J. Griffith, Tiansheng Wang, V. Damagnez, 2015, Journal of medicinal chemistry.

Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships.

P. Charifson, L. Swenson, T. Grossman, 2008, Journal of medicinal chemistry.

Facile preparation of fused ring azolylureas

Tiansheng Wang, S. Tian, D. Deininger, 2007 .

Dual Targeting of GyrB and ParE by a Novel Aminobenzimidazole Class of Antibacterial Compounds

P. Charifson, T. Grossman, E. Olson, 2006, Antimicrobial Agents and Chemotherapy.

Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase γ (PI3Kγ) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS).

J. Griffith, V. Damagnez, S. Mahajan, 2018, Journal of medicinal chemistry.

Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy.

P. Charifson, T. Grossman, Tiansheng Wang, 2014, Bioorganic & Medicinal Chemistry Letters.

Bibliometric analysis of the 100 most-cited papers about the role of gut microbiota in irritable bowel syndrome from 2000 to 2021

Bangmao Wang, Wentian Liu, Qiuyu Chen, 2022, Clinical and Experimental Medicine.

3D QSAR (COMFA) of a series of potent and highly selective VLA-4 antagonists

Herman van Vlijmen, Charles Hammond, Craig Zimmerman, 2002, J. Comput. Aided Mol. Des..

In Vitro Characterization of the Antibacterial Spectrum of Novel Bacterial Type II Topoisomerase Inhibitors of the Aminobenzimidazole Class

P. Charifson, T. Grossman, C. H. Gross, 2006, Antimicrobial Agents and Chemotherapy.

Second-generation antibacterial benzimidazole ureas: discovery of a preclinical candidate with reduced metabolic liability.

P. Charifson, T. Grossman, Tiansheng Wang, 2014, Journal of medicinal chemistry.

Identification of Potent and Novel α4β1 Antagonists Using in Silico Screening

Herman W. T. van Vlijmen, Juswinder Singh, Juswinder Singh, 2002 .